RELATED CONTENT
NEWS
- AAN PREVIEW: Oral drugs make a case for surpassing biologics in MS
- BG-12 filing data put pressure on Aubagio and Gilenya sales strategies
- Bionomics to pursue Kv1.3 leads alone for now as Merck Serono alliance ends
- Sanofi's Lemtrada US/EU filing promises to heat up competition in multiple sclerosis
FEATURES
Other Informa Features

